ClinicalTrials.Veeva

Menu

Myocardial Injury and Quality of Life After COVID-19

V

Voronezh Regional Clinical Consultative and Diagnostic Center

Status

Completed

Conditions

COVID-19
Myocarditis Post Infection
Myocardial Injury

Study type

Observational

Funder types

Other
NETWORK

Identifiers

NCT04794062
08092020

Details and patient eligibility

About

In this observational study follow-up and dynamic observation will be conducted on the participants recovered from pneumonia caused by COVID-19. The main goal is an early diagnosis and detection of myocardial (heart) injury and quality of life in participants recovered from COVID-19 and follow-up in selected participants with present signs of myocarditis and/or myocardial fibrosis.

Full description

The main goal of this observational non-interventional study is the evaluation of prevalence of myocardial injury (heart injury) of the participants recovered from the novel coronavirus infectious disease (COVID-19). Participants with signs of myocarditis (pericarditis) and/or myocardial fibrosis, and with a threat of heart failure development and other outcomes are selected into this study. In this cohort the percentage of participants having myocardial injury based on the level of high-sensitivity troponin, echocardiography (decreased Left Ventricle Ejection Fraction, abnormalities of wall motion, Right Ventricle dysfunction, increased size of heart chambers above referential values, presence of pericardial effusion), cardiac MRI with contrast enhancement (presence of edema on T2-weighted images, presence of early and late gadolinium enhancement phenomenon, local motion abnormalities, increased size of heart chambers above referential values, presence of pericardial effusion). At 6 months of the dynamic follow-up, MRI with contrast enhancement will be repeated in the participants with established myocardial injury at inclusion to assess the percentage of the participants having ongoing myocardial injury.

The secondary goal of the study is evaluation of quality of life of the patients recovered from the novel coronavirus infectious disease (COVID-19) by the means of EQ-5D and/or DASI questionnaire using the descriptive system of 5 components of quality of life related to the wellbeing, and visual analogue scale.

Enrollment

119 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients of age above 18 years with diagnosed SARS-CoV-2 infection based on the PCR (polymerase chain reaction) and/or quantitative tests of IgM and IgG antibodies in serum;
  • Pneumonia development confirmed by chest computed tomography;
  • Negative PCR test for SARS-CoV-2 at the time of inclusion into the study;
  • Stable patient state allowing outpatient follow-up;
  • Signed informed consent.

Exclusion criteria

  • Absence of convincing data confirming SARS-CoV-2 infection of a participant at the time of inclusion;
  • Absence of medical records regarding previous treatment of COVID-19;
  • Low compliance and unwillingness to undergo defined examinations;
  • Absence of informed consent.

Trial design

Trial documents
2

Trial contacts and locations

1

Loading...

Central trial contact

Roman Khokhlov, MD; Leonid Khokhlov, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems